Keavney Bernard, Danesh John, Parish Sarah, Palmer Alison, Clark Sarah, Youngman Linda, Delépine Marc, Lathrop Mark, Peto Richard, Collins Rory
Institute of Human Genetics, University of Newcastle-upon-Tyne, UK.
Int J Epidemiol. 2006 Aug;35(4):935-43. doi: 10.1093/ije/dyl114. Epub 2006 Jul 26.
Blood concentrations of fibrinogen have been associated with coronary heart disease risk in epidemiological studies, but it is uncertain whether this association is causal or reflects residual confounding by other risk factors. We investigated the relationship between the single nucleotide polymorphism at position -148 in the beta-fibrinogen gene promoter (beta - 148C/T), blood fibrinogen levels, and risk of myocardial infarction (MI) in sufficiently large numbers of coronary disease cases to reliably address this question.
Genotyping and measurement of blood fibrinogen concentration were carried out in 4,685 cases of confirmed MI and 3,460 controls with no history of coronary disease. A meta-analysis of ISIS and 19 other studies of beta-fibrinogen genotypes involving a total of 12,220 coronary disease cases and 18,716 controls was conducted.
Among the ISIS controls, mean plasma fibrinogen concentrations with the C/C, C/T and T/T genotypes were 3.34 (SE 0.015), 3.48 (0.022), and 3.60 (0.064) g/l, respectively, corresponding to an increase of 0.14 (0.024) g/l per T allele (trend P < 0.0001). In the case-control comparison, 0.14 g/l higher usual plasma fibrinogen concentration was associated with an age-adjusted and sex-adjusted risk ratio for MI of 1.17 [95% confidence interval (95% CI) 1.14-1.19; P < 0.0001]. But, after further adjustment for smoking, body mass index, and plasma apolipoprotein B/A(1) ratio, this risk ratio fell to 1.03 (95% CI 1.00-1.05; P = 0.05). Moreover, fibrinogen genotype was not significantly associated with MI incidence: risk ratio of 1.06 (95% CI 0.96-1.16) per higher-fibrinogen allele in ISIS alone and of 1.00 (95% CI 0.95-1.04) per allele in the meta-analysis.
Genotypes that produce lifelong differences in fibrinogen concentrations do not materially influence coronary disease incidence. As these genotype-dependent differences in fibrinogen were allocated randomly at conception (Mendelian randomization), this association is not likely to be confounded by other factors. Consequently, these genetic results provide strong evidence that long-term differences in fibrinogen concentrations are not a major determinant of coronary disease risk.
在流行病学研究中,纤维蛋白原的血液浓度与冠心病风险相关,但这种关联是因果关系还是反映了其他风险因素的残余混杂尚不确定。我们在足够多的冠心病病例中研究了β-纤维蛋白原基因启动子-148位单核苷酸多态性(β-148C/T)、血液纤维蛋白原水平与心肌梗死(MI)风险之间的关系,以可靠地解决这个问题。
对4685例确诊的MI患者和3460例无冠心病病史的对照者进行基因分型和血液纤维蛋白原浓度测定。对ISIS研究和其他19项关于β-纤维蛋白原基因型的研究进行荟萃分析,共纳入12220例冠心病病例和18716例对照者。
在ISIS对照者中,C/C、C/T和T/T基因型的平均血浆纤维蛋白原浓度分别为3.34(标准误0.015)、3.48(0.022)和3.60(0.064)g/l,每一个T等位基因对应增加0.14(0.024)g/l(趋势P<0.0001)。在病例对照比较中,通常血浆纤维蛋白原浓度每高0.14g/l,年龄和性别调整后的MI风险比为1.17[95%置信区间(95%CI)1.14-1.19;P<0.0001]。但是,在进一步调整吸烟、体重指数和血浆载脂蛋白B/A(1)比值后,该风险比降至1.03(95%CI 1.00-1.05;P=0.05)。此外,纤维蛋白原基因型与MI发病率无显著关联:仅在ISIS研究中,每增加一个高纤维蛋白原等位基因的风险比为1.06(95%CI 0.96-1.16),在荟萃分析中为每一个等位基因1.00(95%CI 0.95-1.04)。
导致纤维蛋白原浓度产生终生差异的基因型对冠心病发病率没有实质性影响。由于这些纤维蛋白原的基因型依赖性差异在受孕时是随机分配的(孟德尔随机化),这种关联不太可能被其他因素混淆。因此,这些遗传学结果提供了强有力的证据,表明纤维蛋白原浓度的长期差异不是冠心病风险的主要决定因素。